Cevimeline
Evoxac (cevimeline) is a small molecule pharmaceutical. Cevimeline was first approved as Evoxac on 2000-01-11. It is used to treat xerostomia in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M4, and muscarinic acetylcholine receptor M3.
Trade Name | Evoxac |
---|---|
Common Name | Cevimeline |
Indication | xerostomia |
Drug Class | Cholinergic agonists (arecoline derivatives used in treatment of Alzheimer disease) |